- DC Chemicals Limited
- China
- Product Name: Dalbavancin
- Price: $680.0/100mg $1300.0/250mg $2500.0/1g
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Zhejiang Hangyu API Co., Ltd
- China
- Product Name: Dalbavancin Hydrochloride
- Price: ￥Inquiry/1kg
- Purity: 99.5%
- Stocking Period: Inquiry
- Contact: Vinnie
171500-79-1
171500-79-1 structure
- Name: Dalbavancin
- Chemical Name: dalbavancin
- CAS Number: 171500-79-1
- Molecular Formula: C88H100Cl2N10O28
- Molecular Weight: 1816.692
- Catalog: API Antibiotics Peptide
- Create Date: 2018-08-27 19:33:51
- Modify Date: 2024-01-02 14:17:58
-
Dalbavancin is a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens.
| Name | dalbavancin |
|---|---|
| Synonyms |
Dalvance
Zeven Dalbavancin (1S,2R,19R,22R,33S,36R,39R,51S)-5,31-Dichloro-51-{[3-(dimethylamino)propyl]carbamoyl}-2,25,30,43,48-pentahydroxy-46-(α-D-mannopyranosyloxy)-22-(methylamino)-21,34,37,53,55,58-hexaoxo-7,13,27-triox a-20,35,38,52,54,57-hexaazaundecacyclo[37.14.2.2.2.2.2.1.1.1.0.0]hexahexaconta-3,5,8(64),9,11,14,16,23,25,28(59),29,31,40(56),41,43,45,47,49 ,60,62,65-henicosaen-64-yl 2-deoxy-2-[(10-me |
| Description | Dalbavancin is a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens. |
|---|---|
| Related Catalog | |
| Target |
MIC90: 0.06 μg/mL (Staphylococcus aureus) and 0.25 μg/mL (Bacillus anthracis)[1][2] |
| In Vitro | Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents[1][2]. |
| In Vivo | Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens[1]. Animal Model: Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis[1] Dosage: 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg Administration: Intraperitoneal injection; every 36 h or 72 h; for 14 days Result: The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Molecular Formula | C88H100Cl2N10O28 |
| Molecular Weight | 1816.692 |
| Exact Mass | 1814.608521 |
| PSA | 572.51000 |
| LogP | 2.94 |
| Index of Refraction | 1.729 |
| Storage condition | -20℃ |